ELVN · Enliven Therapeutics Inc
United States · RS rating 34 · As of 2026-10-14
| Price | 39.28 USD |
|---|---|
| 1-day change | -0.5% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 8 / 17 / 94 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 35 / 37 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -50.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +35.8% |
| Market cap (USD) | $2.6B |